

This is the English translation of a Japanese press release published on May 8, 2026. If there are any differences in content or interpretation, the Japanese version shall prevail.

May 8, 2026

To Whom It May Concern:

Company name: Hisamitsu Pharmaceutical Co., Inc.
Representative: Kazuhide Nakatomi, President & CEO
(TSE Prime, NSE Premier and FSE Code No. 4530)
Contact: Ken Sakai, Section Manager
Public Relations Section
(TEL: 03-5293-1704)

Notice Concerning Delisting of Company Shares
--

Hisamitsu Pharmaceutical Co., Inc. (the “Company”) hereby announces that at an extraordinary shareholders’ meeting held on April 17, 2026, a proposal regarding a share consolidation was approved as proposed, and as a result, the common shares of the Company will fall under the delisting criteria of Tokyo Stock Exchange, Inc., Nagoya Stock Exchange, Inc., and Fukuoka Stock Exchange and will be delisted as of May 11, 2026.

For details, please refer to the press release titled “Notice Concerning Approval of Share Consolidation, Abolition of Provisions on Share Units, and Partial Amendment of the Articles of Incorporation” by the Company dated April 17, 2026.

The Company would like to express its sincere gratitude to its shareholders and all other related parties for their long-standing understanding of and warm support for the Company’s management.

The Company remains committed to further enhancing its corporate value, and sincerely asks for your continued understanding and support.